Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

1 Nov 2022

Abstract excerpt

Despite improvement in the treatment of medulloblastoma over the last years, numerous patients with MYC- and MYCN-driven tumors still fail current therapies. Medulloblastomas have an intact retinoblastoma protein RB, suggesting that CDK4/6 inhibition might represent a therapeutic strategy for which drug combination remains understudied. We conducted high-throughput drug combination screens in a Group3 (G3)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36318650
DOI: 10.1158/1535-7163.mct-21-0896

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In VivoPMID 36318650Read ↗

Combination of Ribociclib and Gemcitabine for the Treatment of MedulloblastomaSemantic proximity Read ↗

Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapySemantic proximity Read ↗

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) MedulloblastomaSemantic proximity Read ↗

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastomaSemantic proximity Read ↗

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastomaSemantic proximity Read ↗

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastomaSemantic proximity Read ↗

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaSemantic proximity Read ↗

Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activitySemantic proximity Read ↗

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastomaSemantic proximity Read ↗

BET Bromodomain Inhibition of <i>MYC</i> -Amplified MedulloblastomaSemantic proximity Read ↗

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.Semantic proximity Read ↗

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.